











**TENOFOVIR PRODUCTS AVAILABLE IN CANADA**

	Tenofovir alafenamide (TAF)				Tenofovir disoproxil fumarate (TDF)			
	Name	Dosage Form	Dose (adult)	Renal Function Adjustment	Name	Dosage Form	Dose (adult)	Renal Function Adjustment
Single Agent		Not available			<b>Viread®</b> 	TDF 300 mg DIN: 02247128	1 tablet daily.	Clcr 30-49 ml/min: every 48 hours Clcr 10-29 ml/min: every 72-96 hours
NRTI combination	<b>Descovy®</b> 	Emtricitabine 200 mg/TAF 10 mg DIN: 02454416  Emtricitabine 200 mg/TAF 25 mg DIN: 02454424	1 tablet daily.  <i>(*use 10 mg TAF dose if regimen includes cobicistat or ritonavir)</i>	Do not use if Clcr<30 mL/min.	<b>Truvada®</b>   <b>Apo-Emtricitabine-Tenofovir®</b>	Emtricitabine 200 mg/TDF 300 mg DIN: 02274906  Emtricitabine 200 mg/TDF 300 mg DIN: 02452006	1 tablet daily.	Clcr 30-49 ml/min: every 48 hours. Do not use if Clcr<30 mL/min.
Single Tablet Regimens	<b>Genvoya®</b> 	Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/TAF 10 mg DIN: 02449498	1 tablet daily <b>with food.</b>	Do not use if Clcr<30 mL/min.	<b>Stribild®</b> 	Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/TDF 300mg DIN: 02397137	1 tablet daily <b>with food.</b>	Do not initiate if Clcr<70 ml/min. Stop if Clcr<50 mL/min.
	<b>Odefsey®</b> 	Rilpivirine 25 mg/emtricitabine 200 mg/TAF 25 mg DIN: 02461463	1 tablet daily <b>with a meal.</b>	Do not use if Clcr<30 mL/min.	<b>Complera®</b> 	Rilpivirine 25 mg/emtricitabine 200 mg/TDF 300 mg DIN: 02374129	1 tablet daily <b>with food.</b>	Do not use if Clcr<50 mL/min.
					<b>Atripla®</b> 	Efavirenz 600 mg/emtricitabine 200 mg/TDF 300 mg DIN: 02300699	1 tablet daily <b>on an empty stomach.</b>	Do not use if Clcr<50 mL/min.
For Hepatitis B	<b>Vemlidy®</b> 	TAF 25 mg DIN: 02464241	1 tablet daily.	Not recommended if Clcr<15 mL/min.	<b>Viread®</b> 	See Viread information above.		

References: Descovy Product Monograph, Gilead Sciences, April 28, 2016; Genvoya Product Monograph, Gilead Sciences, December 16, 2016; Odefsey Product Monograph, Gilead Sciences, February 9, 2017; Vemlidy Product Monograph, Gilead Sciences, May 17, 2017; Viread Product Monograph, Gilead Sciences, October 21, 2016; Truvada Product Monograph, Gilead Sciences, October 26, 2016; Apo-Emtricitabine-Tenofovir Product Monograph, Apotex Inc., May 15, 2017; Stribild Product Monograph, Gilead Sciences, March 7, 2017; Complera Product Monograph, Gilead Sciences, February 21, 2017; Atripla Product Monograph, Gilead Sciences, December 2, 2016.

Prepared by A. Tseng, Pharm.D., May 31, 2017.